These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 18442180)

  • 1. Advanced glycation end products and diabetic foot disease.
    Huijberts MS; Schaper NC; Schalkwijk CG
    Diabetes Metab Res Rev; 2008; 24 Suppl 1():S19-24. PubMed ID: 18442180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced glycoxidation products and impaired diabetic wound healing.
    Peppa M; Stavroulakis P; Raptis SA
    Wound Repair Regen; 2009; 17(4):461-72. PubMed ID: 19614910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of advanced glycation end products and their receptors in development of diabetic neuropathy.
    Wada R; Yagihashi S
    Ann N Y Acad Sci; 2005 Jun; 1043():598-604. PubMed ID: 16037282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced glycation end products: sparking the development of diabetic vascular injury.
    Goldin A; Beckman JA; Schmidt AM; Creager MA
    Circulation; 2006 Aug; 114(6):597-605. PubMed ID: 16894049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAGE biology, atherosclerosis and diabetes.
    Barlovic DP; Soro-Paavonen A; Jandeleit-Dahm KA
    Clin Sci (Lond); 2011 Jul; 121(2):43-55. PubMed ID: 21457145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
    Jandeleit-Dahm K; Watson A; Soro-Paavonen A
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):329-34. PubMed ID: 18290873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RAGE pathway: activation and perpetuation in the pathogenesis of diabetic neuropathy.
    Lukic IK; Humpert PM; Nawroth PP; Bierhaus A
    Ann N Y Acad Sci; 2008 Apr; 1126():76-80. PubMed ID: 18448798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
    Nishizawa Y; Koyama H
    J Ren Nutr; 2008 Jan; 18(1):76-82. PubMed ID: 18089449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
    Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T
    Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AGE-RAGE and AGE Cross-link interaction: important players in the pathogenesis of diabetic kidney disease.
    Jensen LJ; Østergaard J; Flyvbjerg A
    Horm Metab Res; 2005 Apr; 37 Suppl 1():26-34. PubMed ID: 15918107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
    Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.
    Yan SF; Ramasamy R; Schmidt AM
    Nat Clin Pract Endocrinol Metab; 2008 May; 4(5):285-93. PubMed ID: 18332897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AGE, RAGE, and ROS in diabetic nephropathy.
    Tan AL; Forbes JM; Cooper ME
    Semin Nephrol; 2007 Mar; 27(2):130-43. PubMed ID: 17418682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.
    Cameron NE; Gibson TM; Nangle MR; Cotter MA
    Ann N Y Acad Sci; 2005 Jun; 1043():784-92. PubMed ID: 16037306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology and treatment of diabetic erectile dysfunction.
    Moore CR; Wang R
    Asian J Androl; 2006 Nov; 8(6):675-84. PubMed ID: 16892168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.
    Yamagishi S; Nakamura K; Matsui T; Ueda S; Noda Y; Imaizumi T
    Cardiovasc Ther; 2008; 26(1):50-8. PubMed ID: 18466420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells.
    Takahashi HK; Mori S; Wake H; Liu K; Yoshino T; Ohashi K; Tanaka N; Shikata K; Makino H; Nishibori M
    J Pharmacol Exp Ther; 2009 Jul; 330(1):89-98. PubMed ID: 19380603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.
    Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
    Med Hypotheses; 2005; 64(6):1208-10. PubMed ID: 15823719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.